Company Presentation
Ymmunobio
| Country: | Switzerland |
| Category: | Emerging Biotech Company |
| Room: | Singapore |
| Date: | April 22, 2024 |
| Time: | 15:15 – 15:30 |
| Website: | www.ymmuno.bio |
| Speaker: | Dr. Peter Schiemann, CEO & Chairman |
Company profile
Ymmunobio was founded in 2021 focusing on GI cancers with our lead indication of gastric cancer. Our new and first in class Antibody Drug Conjugate (ADC) candidate (YB-800) has a vast potential in addressing GI cancer. The new receptor target is present on 50% of GI cancers. Ymmunobio functions as a completely virtual company. Our team consists of very experienced Subject Matter Experts who have been working in the industry for decades.
